Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,293 total articles
Puma Biotechnology Inc. (NASDAQ:PBYI) President and CEO Alan H. Auerbach completed a sale of 44,058 common shares on July 6, 2026, generating $364,051 in proceeds. The transaction was executed under a Rule 10b5-1 trading plan initiated in December 2020. This activity coincides with the stock trading near its 52-week high of $8.44, a period marked b…
Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc. (NASDAQ:PBYI), executed a sale of 8,460 shares of common stock on July 6, 2026, generating $69,904 in proceeds. The transaction was part of a pre-arranged 10b5-1(c) plan established in December 2020, leaving Hunt with a direct holding of 196,841 shares. This sa…
Omada Health, Inc. (NASDAQ:OMDA) Chief Accounting Officer Craig Gracey has executed a series of stock sales totaling $85,423, conducted under the parameters of a 10b5-1 trading plan established in March 2026. The transactions, detailed in an amended Form 4/A filing submitted to the Securities and Exchange Commission on July 8, 2026, involve the liq…
Craig Gracey, Chief Accounting Officer at Omada Health, Inc. (NASDAQ:OMDA), executed a same-day exercise and sale of 2,083 shares on June 24, 2026, netting approximately $39,601. The transaction, conducted under a 10b5-1 plan adopted in March 2026, was reported via an amended Form 4. The sale occurred as OMDA stock reached $22.98, up 49% over six m…
Omada Health Inc. (NASDAQ:OMDA) Chief Financial Officer Steven L. Cook has sold 50,950 shares of company stock in late June, realizing approximately $1,034,616 in proceeds. The transactions were facilitated through a pre-arranged 10b5-1 trading plan established on March 14, 2026. Prior to the sale, Cook exercised stock options for the same number o…
Maximo F. Nougues, Chief Financial Officer at Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 9,386 shares of common stock on July 6, 2026, for $77,556 at $8.263 per share. The transaction was part of a Rule 10b5-1(c) sell-to-cover program established December 14, 2020. Post-sale, Nougues holds 230,637 shares directly. PBYI stock trades near its 52-we…
Omada Health, Inc. (OMDA) Chief Accounting Officer Craig Gracey executed a series of stock transactions on June 12, 2026, selling $120,123 worth of shares under a pre-arranged 10b5-1 trading plan. This activity occurs against a backdrop of strong recent stock performance, with OMDA up 49% over six months, and positive Q1 2026 financial results that…
EverCommerce Inc. (NASDAQ: EVCM) President Matthew David Feierstein executed a series of stock sales totaling $219,279 between July 6 and July 8, 2026. The transactions involved 21,798 shares, conducted under a Rule 10b5-1 trading plan established in August 2025. This activity occurs against a backdrop of recent financial results where the company …
Omada Health, Inc. (OMDA) reported a routine insider transaction involving Chief Accounting Officer Craig Gracey, who executed a sale of company shares valued at $37,494 on June 22, 2026. The transaction was part of a pre-arranged trading plan and involved both the exercise of stock options and the subsequent sale of common stock. The filing also c…
Globalharvest Holdings Venture Ltd has significantly increased its position in Mission Produce, Inc. (NASDAQ:AVO) through a substantial equity acquisition. The transaction involves the purchase of 650,415 shares at a weighted average price of $12.73, bringing the entity's total direct ownership to 11,191,352 shares. This acquisition occurs as Missi…
William Earl Cooper, the Chief Financial Officer at Everspin Technologies, executed a transaction to sell 1,821 shares of the company's common stock on July 6, 2026. The sale, valued at $35,782, was necessitated by the requirement to cover tax liabilities associated with the vesting of restricted stock units. Following this divestment, Cooper retai…
William Earl Cooper, Chief Financial Officer of Everspin Technologies Inc. (NASDAQ: MRAM), executed a sale of company shares on April 2, 2026, as detailed in an amended Form 4 filing with the Securities and Exchange Commission. The transaction involved the disposal of 1,627 shares at $8.80 per share, totaling $14,317, specifically to cover tax liab…
Kevin Tang and Tang Capital Management LLC, key stakeholders in Boundless Bio, Inc. (NASDAQ:BOLD), have executed a series of stock acquisitions totaling $141,864. These transactions, completed between July 6 and July 8, 2026, occur as the company prepares for a definitive merger with clinical-stage biotechnology firm Serapha Bio. The insider buying…
Everspin Technologies Inc. (NASDAQ:MRAM) reported an insider transaction involving President and CEO Sanjeev Aggarwal, who sold shares to satisfy tax liabilities from restricted stock unit vesting. The sale coincides with significant corporate developments, including a major defense contract and an analyst upgrade, contrasting with skepticism from …
Sean Michael Dougherty, Vice President of Sales at Everspin Technologies Inc. (NASDAQ: MRAM), executed a stock sale on July 6, 2026, to satisfy tax withholding obligations. The transaction occurs as the company navigates significant corporate developments, including a major defense industry contract, index inclusion, and shareholder-approved equity…
Evommune director Arthur S. Kirsch executed a $133,000 purchase of 10,000 shares on July 7, 2026. The transaction occurred as the stock traded near its 52-week low, despite recent analyst downgrades triggered by a failed Phase 2b clinical trial for EVO756 in chronic spontaneous urticaria. Kirsch holds the shares through a family trust where he serv…
William Guyer, Chief Development Officer at CORCEPT THERAPEUTICS INC (NASDAQ:CORT), executed the sale of 20,000 shares of the company's common stock on July 7, 2026, generating approximately $1.86 million in proceeds. The transaction was facilitated through a pre-arranged 10b5-1 trading plan adopted on November 27, 2024. This sale coincides with CO…
Javier Olivan, Chief Operating Officer of Meta Platforms, Inc. (NASDAQ:META), executed a sale of Class A Common Stock valued at approximately $3.15 million on July 6, 2026. The transaction involved the liquidation of 5,235 shares across direct and indirect holdings, adhering to a Rule 10b5-1 trading plan established in late 2025. This executive act…
Atay Oguzhan, Chairman and CEO of BillionToOne Inc. (NASDAQ:BLLN), executed significant transactions involving the company's Class A Common Stock on July 6, 2026, under a Rule 10b5-1 trading plan. The transactions included the sale of approximately $4.7 million in shares and the acquisition of 26,250 shares through the exercise of vested stock opti…
Michael L Speiser, a director at Snowflake Inc. (NASDAQ: SNOW), executed a significant divestment of company equity on July 6, 2026, selling approximately $12.2 million worth of shares. The transaction was facilitated through a pre-arranged 10b5-1 trading plan established in late 2024, ensuring compliance with regulatory frameworks for insider trad…
Michael L. Speiser, a director at Snowflake Inc., executed a sale of common stock totaling approximately $216,641 on July 6, 2026. The transaction involved 840 shares sold via an indirect holding through a trust, following a pre-arranged 10b5-1 trading plan established in late 2024. This sale occurred as Snowflake's stock traded near its 52-week hi…
Michael L Speiser, a director at Snowflake Inc. (SNOW), executed a sale of common stock totaling $649,925 on July 6, 2026. The transaction involved shares held indirectly through trusts where Mr. Speiser serves as trustee, adhering to a pre-arranged 10b5-1 trading plan established in December 2024. Following the sale, Mr. Speiser retains indirect o…
Arvind Nithrakashyap, Chief Technology Officer at Rubrik, Inc., executed a series of sales totaling 38,460 shares of Class A Common Stock between July 6 and July 8, 2026. The transactions, valued at approximately $3.33 million, were conducted under a Rule 10b5-1 trading plan established in October 2025. This activity occurs as Rubrik reports financ…
Robert Baltera Jr., a director at Palisade Bio, Inc. (NASDAQ: PALI), has acquired an additional $102,084 worth of the company's common stock through two separate transactions in early July 2026. This insider buying activity occurs as Palisade Bio advances its clinical pipeline, having recently secured FDA clearance for an Investigational New Drug a…
Palisade Bio, Inc. (NASDAQ: PALI) reported significant insider activity as Chief Medical Officer Mitchell Lawrence Jones executed a stock sale on July 7, 2026. The transaction was necessitated by tax withholding requirements following the vesting of Restricted Stock Units (RSUs). This financial maneuver occurs against a backdrop of clinical progres…
